Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months
- Author(s)
- Mordant, FL; Price, OH; Rudraraju, R; Slavin, MA; Marshall, C; Worth, LJ; Peck, H; Barr, IG; Sullivan, SG; Subbarao, K;
- Journal Title
- Influenza and Other Respiratory Viruses
- Publication Type
- Research article
- Abstract
- BACKGROUND: In Australia, seasonal inactivated influenza vaccine is typically offered in April. However, the onset, peak and end of a typical influenza season vary, and optimal timing for vaccination remains unclear. Here, we investigated vaccine-induced antibody response kinetics over 6 months in different age groups. METHODS: We conducted a prospective serosurvey among 71 adults aged 18-50 years, 15 community-dwelling ('healthy') and 16 aged-care facility resident ('frail') older adults aged >/=65 years who received the 2018 southern hemisphere vaccines. Sera were collected at baseline, and 1, 2, 4, and 6 months post-vaccination. Antibody titres were measured by haemagglutination inhibition or microneutralisation assays. Geometric mean titres were estimated using random effects regression modelling and superimposed on 2014-2018 influenza season epidemic curves. RESULTS: Antibody titres peaked 1.2-1.3 months post-vaccination for all viruses, declined by 3 months post-vaccination but, notably, persisted above baseline after 6 months in all age groups by 1.3- to 1.5-fold against A(H1N1)pdm09, 1.7- to 2-fold against A(H3N2), 1.7- to 2.1-fold against B/Yamagata and 1.8-fold against B/Victoria. Antibody kinetics were similar among different age groups. Antibody responses were poor against cell-culture grown compared to egg-grown viruses. CONCLUSIONS: These results suggest subtype-specific antibody-mediated protection persists for at least 6 months, which corresponds to the duration of a typical influenza season.
- Publisher
- Wiley
- Keywords
- Humans; Aged; *Influenza, Human; *Influenza Vaccines; Seasons; Vaccines, Inactivated; *Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Prospective Studies; Antibodies, Viral; Vaccination; Hemagglutination Inhibition Tests
- Department(s)
- Infectious Diseases
- PubMed ID
- 36451293
- Publisher's Version
- https://doi.org/10.1111/irv.13072
- Open Access at Publisher's Site
https://doi.org/10.1111/irv.13072- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-06 06:44:12
Last Modified: 2023-06-06 06:45:18